Product Description
Mechanisms of Action: PDK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia | India | Peru | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: University of Florida
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Insulin Resistance
Phase 3: Acidosis, Lactic|Pyruvate Dehydrogenase Complex Deficiency Disease
Phase 2: Healthy Volunteers|Glioblastoma|Head and Neck Cancer|Squamous Cell Carcinoma|Multiple Myeloma|Non-Small-Cell Lung Cancer|Glioma|Breast Cancer|Acidosis, Lactic|MELAS Syndrome
Phase 1: MELAS Syndrome|Liver Cancer|Brain Cancer|Evans Syndrome|Acidosis, Lactic|Glioblastoma|Potassium Deficiency|Lung Cancer|Brain Death|Tumor Lysis Syndrome|Protein Deficiency|Breast Cancer|Head and Neck Cancer|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Pyruvate Dehydrogenase Complex Deficiency Disease|Deficiency Diseases|Brain Injuries|Mitochondrial Diseases|Hyperglycemia|Type 1 Diabetes|Hypoglycemia|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DCA | P2 |
Not yet recruiting |
Glioblastoma |
2026-12-30 |
|
| NCT05317455 | P1 |
Not yet recruiting |
Type 1 Diabetes|Hypoglycemia |
2025-10-01 |
|
| Application of a new portable ultrasonic diagnostic instrument | N/A |
Recruiting |
Other |
2025-07-31 |
|
| ACTRN12623001164684 | N/A |
Not yet recruiting |
Nose Cancer |
2025-06-30 |